It was announced on April 17 that a major global pharmaceutical and medical device event will be held this October in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, with the China-Portuguese (Spanish) Speaking Countries Economic and Trade Service Center, the Hengqin Guidance Fund, and IQVIA, a global leading CRO provider, having signed a strategic cooperation agreement to back the event.
IQVIA, a U.S.-based Fortune 500 company, boasts 93,000 employees across more than 100 countries and regions. It has been named one of Fortune's "Most Admired Companies" for nine consecutive years, and ranks among the world's largest clinical research outsourcing providers as well as a leader in pharmaceutical consulting services.
At the signing ceremony, the three parties signed a memorandum. IQVIA also launched a clinical operations center for an AI-powered CRO incubated in China. In addition, IQVIA and the trade service center signed a strategic agreement. The Hengqin Guidance Fund, managed by CICC Capital, and a healthcare-focused fund initiated by IQVIA also signed a letter of intent for investment cooperation.
The Cooperation Zone is stepping up efforts to help innovative drugs and medical devices expand overseas. By leveraging the integrated policy advantages of Macao SAR and Hengqin, it aims to support local innovators in entering global markets. Backed by its global clinical service network and robust commercialization capabilities, IQVIA will assist Macao-Hengqin in building a globally competitive life sciences innovation hub.
Reporter | Dai Bosi
Photo | Hengqin Online
